- Reports /
- Veterinary Molecular Diagnostics Market
Veterinary Molecular Diagnostics Market
Veterinary Molecular Diagnostics Market Market Research Report – Segmented By Product (Instruments, Kit and Reagents, Software and Services), By Application (Infectious Diseases, Genetics, Other Applications), By Technology (PCR, Microarray, DNA Sequencing) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Product
- By Application
- By Technology
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
Veterinary Molecular Diagnostics Market was valued at US $7.38 billion in 2021 and is projected to grow at 11.28% CAGR over the forecast period to reach US $14.01 billion by 2027. Veterinary Molecular Diagnostics Market represented US $1.42 billion opportunity over 2019-2021 and estimated to create US $6.63 billion opportunity in 2027 over 2021.
Veterinary Molecular Diagnostics from Consainsights analyses the Veterinary Molecular Diagnostics Market in the Life Sciences industry over the forecast period to 2027.
Veterinary Molecular Diagnostics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Veterinary Molecular Diagnostics segmentation includes Product, Application, Technology and Geography.
Based on the Product, the Veterinary Molecular Diagnostics analysis covers Instruments, Kit and Reagents, Software and Services.
In Product segment, Instruments segment has highest cagr growth of 9.97%.
Based on the Application, the Veterinary Molecular Diagnostics analysis covers Infectious Diseases, Genetics, Other Applications.
In Application segment, Infectious Diseases segment has highest cagr growth of 9.97%.
Based on the Technology, the Veterinary Molecular Diagnostics analysis covers PCR, Microarray, DNA Sequencing.
In Technology segment, PCR segment has highest cagr growth of 9.97%.
Based on the region, the Veterinary Molecular Diagnostics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include Biochek BV, Biomerieux SA, Bioneer Corporation, Idexx Laboratories Inc., Ingenetix GmbH, Neogen Corporation, Thermo Fischer Scientific Inc., Veterinary Molecular Diagnostics Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Product
Introduction
In 2021, Instruments segment has the highest revenue of US $3.97 billion and is expected to grow at CAGR of 9.97% by 2027 Instruments segment has highest cagr growth of 9.97%.
Instruments
Instruments segment was valued at US $3.20 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $7.53 billion by 2027. Instruments segment represented US $0.76 billion opportunity over 2019-2021 and estimated to create US $3.57 billion opportunity in 2027 over 2021.
Kit and Reagents
Kit and Reagents segment was valued at US $1.37 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $3.23 billion by 2027. Kit and Reagents segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.53 billion opportunity in 2027 over 2021.
Software and Services
Software and Services segment was valued at US $1.38 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $3.25 billion by 2027. Software and Services segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.54 billion opportunity in 2027 over 2021.
Application
Introduction
In 2021, Infectious Diseases segment has the highest revenue of US $3.19 billion and is expected to grow at CAGR of 9.97% by 2027 Infectious Diseases segment has highest cagr growth of 9.97%.
Infectious Diseases
Infectious Diseases segment was valued at US $2.58 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $6.06 billion by 2027. Infectious Diseases segment represented US $0.61 billion opportunity over 2019-2021 and estimated to create US $2.87 billion opportunity in 2027 over 2021.
Genetics
Genetics segment was valued at US $1.87 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $4.40 billion by 2027. Genetics segment represented US $0.45 billion opportunity over 2019-2021 and estimated to create US $2.09 billion opportunity in 2027 over 2021.
Other Applications
Other Applications segment was valued at US $1.51 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $3.55 billion by 2027. Other Applications segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $1.68 billion opportunity in 2027 over 2021.
Technology
Introduction
In 2021, PCR segment has the highest revenue of US $3.38 billion and is expected to grow at CAGR of 9.97% by 2027 PCR segment has highest cagr growth of 9.97%.
PCR
PCR segment was valued at US $2.73 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $6.42 billion by 2027. PCR segment represented US $0.65 billion opportunity over 2019-2021 and estimated to create US $3.04 billion opportunity in 2027 over 2021.
Microarray
Microarray segment was valued at US $1.70 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $3.99 billion by 2027. Microarray segment represented US $0.40 billion opportunity over 2019-2021 and estimated to create US $1.89 billion opportunity in 2027 over 2021.
DNA Sequencing
DNA Sequencing segment was valued at US $1.53 billion in 2019 and is projected to grow at 9.97% CAGR over the forecast period to reach US $3.60 billion by 2027. DNA Sequencing segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.71 billion opportunity in 2027 over 2021.